| Literature DB >> 34903540 |
Markku Partinen1,2, Brigitte Holzinger3, Charles M Morin4, Colin Espie5, Frances Chung6, Thomas Penzel7, Christian Benedict8, Courtney J Bolstad9, Jonathan Cedernaes10,11, Rachel Ngan Yin Chan12, Yves Dauvilliers13, Luigi De Gennaro14,15, Fang Han16, Yuichi Inoue17,18, Kentaro Matsui19,20, Damien Leger21,22, Ana Suely Cunha23, Ilona Merikanto24, Sergio Mota-Rolim25,26, Michael Nadorff9, Giuseppe Plazzi27,28, Jules Schneider5, Mariusz Sieminski29, Yun-Kwok Wing12, Bjørn Bjorvatn30,31.
Abstract
OBJECTIVES: Sleep is important for human health and well-being. No previous study has assessed whether the COVID-19 pandemic impacts sleep and daytime function across the globe.Entities:
Keywords: COVID-19; anxiety disorders; epidemiology; neurology; sleep medicine; social medicine
Mesh:
Year: 2021 PMID: 34903540 PMCID: PMC8671846 DOI: 10.1136/bmjopen-2021-050672
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Characteristics of the study population
| % (N=25 454) | |
| Gender (n=24 353) | |
| Male | 33.9 (8257) |
| Female | 66.0 (16 081) |
| Other | 0.1 (15) |
| Age (years) (n=24 218) | |
| <25 | 14.9 (3613) |
| 25–34 | 25.4 (6160) |
| 35–44 | 18.7 (4525) |
| 45–54 | 16.6 (4018) |
| 55–64 | 13.4 (3253) |
| 65+ | 10.9 (2649) |
| Marital status (n=24 264) | |
| Single | 36.3 (8814) |
| Cohabiting | 56.0 (13 578) |
| Divorced/separated | 6.1 (1467) |
| Widowed | 1.7 (405) |
| Education (n=24 069) | |
| Below university | 73.2 (17 619) |
| College/university | 26.8 (6450) |
| Ethnicity (n=23 935) | |
| Caucasian/white | 44.2 (10 588) |
| Asian | 40.2 (9632) |
| Other | 15.5 (3715) |
| COVID-19 (n=24 497) | |
| No | 79.5 (19 464) |
| Yes | 3.0 (739) |
| Do not know | 17.5 (4294) |
| Confinement (n=23 072) | |
| No | 57.8 (13 339) |
| Two weeks or less | 8.6 (1987) |
| 3–4 weeks | 5.1 (1187) |
| 5–6 weeks | 4.0 (926) |
| 7–8 weeks | 5.4 (1240) |
| More than 8 weeks | 19.0 (4393) |
| Financial suffering (n=24 324) | |
| Not at all | 44.1 (10 718) |
| A little | 28.4 (6907) |
| Somewhat | 15.1 (3662) |
| Much | 8.4 (2037) |
| Very much/severely | 4.1 (1000) |
| Country (n=25 484) | |
| Austria | 3.3 (722) |
| Brazil | 8.2 (1821) |
| Canada | 9.4 (2080) |
| China/Jilin | 4.8 (1071) |
| China/Hongkong | 8.1 (1790) |
| Finland | 3.9 (869) |
| France | 4.9 (1089) |
| Italy | 6.5 (1439) |
| Japan | 30.5 (6744) |
| Norway | 4.8 (1060) |
| Poland | 2.0 (433) |
| Sweden | 3.3 (733) |
| UK | 5.7 (1257) |
| USA | 4.7 (1043) |
Figure 1(A, B) Prevalence of all sleep problems before and during the pandemic. There was a statistically significant difference in the prevalence before and during the pandemic for all sleep problems (p<0.0001). Error bars represent SD.
Sleep and daytime problems among all participants in the International COVID-19 Sleep Study study (N=25 484).
| All countries | Before pandemic (CI) | During pandemic (CI) | Improved | Unchanged | Worsened |
| Poor sleep quality* | 12.5% (11.8% to 13.2%) | 28.2% (27.1% to 29.3%)† | 5.2% | 74.0% | 20.8% |
| Sleep onset problems‡ | 14.8% (13.9% to 15.7%) | 27.9% (26.9% to 29.1%)† | 4.4% | 77.8% | 17.8% |
| Sleep maintenance problems§ | 17.1% (16.2% to 18.1%) | 27.9% (26.8% to 29.1%)† | 4.2% | 80.6% | 15.2% |
| Early morning awakening¶ | 13.6% (12.7% to 14.5%) | 21.7% (20.6% to 22.7%)† | 5.0% | 81.8% | 13.2% |
| Nightmares** | 8.5% (7.7% to 9.4%) | 15.0% (14.0% to 16.0%)† | 2.9% | 87.6% | 9.5% |
| Hypnotic use†† | 7.8% (7.1% to 8.6%) | 12.2% (11.2% to 13.2%)† | 2.4% | 90.7% | 6.9% |
| Fatigue‡‡ | 20.7% (19.8% to 21.7%) | 29.9% (28.8% to 31.0%)† | 8.0% | 74.9% | 17.1% |
| Excessive sleepiness§§ | 18.5% (17.6% to 19.5%) | 27.7% (26.6% to 28.9%)† | 6.9% | 76.9% | 16.2% |
*Proportion reporting sleep quality ‘rather badly’ or ‘badly’.
†Statistically significant difference from before pandemic (p<0.0001).
‡Proportion reporting sleep onset problems 3+ days/week.
§Proportion reporting sleep maintenance problems 3+ day/week.
¶Proportion reporting early morning awakening problems 3+ days/week.
**Proportion reporting nightmares 3+ nights/week.
††Hypnotic use 3+ days/week.
‡‡Proportion reporting fatigue 3+ days/week.
§§Proportion reporting excessive daytime sleepiness 3+ days/week.
Prevalence (%) of sleep and daytime problems depending on COVID-19, confinement and financial problems due to the pandemic (n=22 151)
| Poor sleep quality* | SO problems† | SM problems‡ | EMA problems§ | Nightmares¶ | Hypnotic use** | Fatigue†† | Excessive sleepiness‡‡ | |
| COVID-19 | ||||||||
| Yes (%) (CI) | 34.3 (29.2 to 39.9) | 31.2 (26.2 to 36.7) | 32.9 (27.6 to 38.6) | 32.8 (27.6 to 38.5) | 27.8 (22.8 to 33.5) | 28.5 (23.4 to 34.3) | 36.0 (30.7 to 41.6) | 40.8 (35.2 to 46.6) |
| No (%) (CI) | 27.8 (26.7 to 28.9) | 27.7 (26.6 to 28.8) | 27.5 (26.4 to 28.7) | 20.8 (19.7 to 21.8) | 14.0 (13.0 to 15.0) | 10.9 (10.0 to 11.9) | 29.4 (28.3 to 30.6) | 26.7 (25.6 to 27.8) |
| OR adjusted 1§§ | 1.62 (1.26 to 2.07) | 1.35 (1.04 to 1.75) | 1.42 (1.09 to 1.84) | 1.93 (1.48 to 2.50) | 2.05 (1.53 to 2.75) | 2.68 (2.00 to 3.60) | 1.43 (1.11 to 1.83) | 1.92 (1.49 to 2.46) |
| OR adjusted 2¶¶ | 1.71 (1.31 to 2.22) | 1.27 (0.94 to 1.72) | 1.25 (0.89 to 1.77) | 1.64 (1.20 to 2.47) | 1.59 (1.09 to 2.33) | 1.83 (1.15 to 2.91) | 1.35 (1.01 to 1.79) | 1.72 (1.29 to 2.30) |
| OR fully adjusted*** | 1.55 (1.18 to 2.03) | 1.11 (0.82 to 1.52) | 1.12 (0.79 to 1.59) | 1.48 (1.07 to 2.04) | 1.19 (0.80 to 1.76) | 1.44 (0.88 to 2.35) | 1.20 (0.89 to 1.61) | 1.51 (1.13 to 2.02) |
| Confinement | ||||||||
| Yes (%) (CI) | 30.3 (28.8 to 31.8) | 31.9 (30.4 to 33.4) | 29.6 (28.1 to 31.2) | 23.2 (21.8 to 24.7) | 17.4 (16.1 to 18.8) | 13.5 (12.3 to 14.9) | 32.6 (31.0 to 34.2) | 30.8 (29.3 to 32.4) |
| No (%) (CI) | 24.4 (22.9 to 25.8) | 20.4 (18.9 to 21.9) | 24.7 (23.1 to 26.2) | 18.8 (17.3 to 20.3) | 10.8 (9.4 to 12.3) | 10.0 (8.7 to 11.5) | 24.8 (23.2 to 26.4) | 22.0 (20.5 to 23.7) |
| OR adjusted 1§§ | 1.37 (1.22 to 1.53) | 1.67 (1.47 to 1.88) | 1.42 (1.25 to 1.60) | 1.38 (1.20 to 1.59) | 1.56 (1.30 to 1.88) | 1.42 (1.16 to 1.74) | 1.36 (1.20 to 1.53) | 1.46 (1.29 to 1.65) |
| OR adjusted 2¶¶ | 1.37 (1.22 to 1.54) | 1.35 (1.11 to 1.63) | 1.30 (1.11 to 1.53) | 1.30 (1.12 to 1.53) | 1.60 (1.30 to 1.96) | 1.30 (1.01 to 1.68) | 1.35 (1.18 to 1.53) | 1.24 (1.06 to 1.45) |
| OR fully adjusted*** | 1.19 (1.02 to 1.37) | 1.28 (1.09 to 1.50) | 1.15 (0.97 to 1.36) | 0.95 (0.80 to 1.13) | 1.09 (0.84 to 1.43) | 0.70 (0.53-0-92) | 1.02 (0.87 to 1.18) | 1.07 (0.91 to 1.25) |
| Suffered financially | ||||||||
| Yes (%) (CI) | 33.7 (30.6 to 36.9) | 34.3 (31.1 to 37.7) | 33.6 (30.4 to 37.0) | 31.1 (28.0 to 34.5) | 25.0 (21.9 to 28.4) | 22.3 (19.2 to 25.7) | 37.8 (34.5 to 41.2) | 36.2 (32.9 to 39.6) |
| No (%) (CI) | 27.3 (26.2 to 28.4) | 26.7 (25.6 to 27.9) | 26.8 (25.7 to 28.0) | 19.9 (18.8 to 21.0) | 13.0 (12.1 to 14.1) | 10.3 (9.4 to 11.3) | 28.4 (27.2 to 29.6) | 26.2 (25.0 to 27.4) |
| OR adjusted 1§§ | 1.44 (1.23 to 1.69) | 1.46 (1.24 to 1.73) | 1.47 (1.25 to 1.73) | 1.87 (1.57 to 2.23) | 2.06 (1.68 to 2.53) | 2.29 (1.84 to 2.86) | 1.57 (1.34 to 1.84) | 1.61 (1.37 to 1.90) |
| OR adjusted 2¶¶ | 1.45 (1.22 to 1.72) | 1.40 (1.15 to 1.70) | 1.36 (1.10 to 1.67) | 1.72 (1.41 to 2.09) | 1.68 (1.31 to 2.16) | 2.10 (1.56 to 2.83) | 1.47 (1.23 to 1.77) | 1.56 (1.29 to 1.89) |
| OR fully adjusted 2*** | 1.38 (1.16 to 1.64) | 1.36 (1.12 to 1.66) | 1.32 (1.07 to 1.64) | 1.67 (1.36 to 2.05) | 1.67 (1.29 to 2.16) | 2.03 (1.50 to 2.75) | 1.44 (1.20 to 1.73) | 1.50 (1.23 to 1.82) |
All countries are included in the analyses.
*Proportion reporting sleep quality ‘rather badly’ or ‘badly’.
†Proportion reporting SO problems 3+ days/week.
‡Proportion reporting SM problems 3+ days/week.
§Proportion reporting EMA problems 3+ days/week.
¶Proportion reporting nightmares 3+ nights/week.
**Hypnotic use 3+ days/week.
††Proportion reporting fatigue 3+ days/week.
‡‡Proportion reporting excessive daytime sleepiness 3+ days/week.
§§OR with adjustment for gender, age, marital status (single, cohabiting, divorced/separated or widowed) and education (below university or university).
¶¶OR adjusted in addition to ethnicity (Asian, Caucasian/European or other) and also for the presence of the problem before COVID-19.
***Fully adjusted model: OR adjusted in addition to the other factors (presence of COVID-19, financial suffering and confinement) and also the severity of the COVID-19 epidemic in each country at the moment of the survey as measured by cumulative number of cases per 100 000 at the median time of the survey in each country. Results are weighted and stratified by countries.
EMA, early morning awakening; SM, sleep maintenance; SO, sleep onset.